Table 5. Distribution of surgical RR and ROM before and after implementation of the BRAFV600E mutation and ACR TI-RADS.
| TBSRTC categories | 2010–2014, n (%) | 2017–2018, n (%) | P value |
|---|---|---|---|
| Diagnoses | |||
| I (ND) | 166 (6.3)a | 116 (6.1)a | |
| RR | 65 (39.1)b | 25 (21.6)b | <0.01* |
| ROM | 27 (41.5)c | 20 (80.0)c | <0.01* |
| II (benign) | 753 (28.5)a | 305 (16.0)a | |
| RR | 85 (11.3)b | 17 (5.6)b | 0.049* |
| ROM | 7 (8.2)c | 4 (23.5)c | <0.01* |
| III (AUS/FLUS) | 144 (5.4)a | 108 (5.7)a | |
| RR | 52 (36.1)b | 18 (16.7)b | <0.01* |
| ROM | 18 (34.6)c | 9 (50.0)c | <0.01* |
| IV (FN/SFN) | 109 (4.1)a | 122 (6.4)a | |
| RR | 51 (46.8)b | 40 (32.8)b | <0.01* |
| ROM | 28 (54.9)c | 18 (45.0)c | 0.012* |
| V (SFM) | 172 (6.5)a | 104 (5.4)a | |
| RR | 123 (71.5)b | 75 (72.1)b | 0.874 |
| ROM | 111 (90.2)c | 71 (94.7)c | 0.098 |
| VI (malignant) | 1,299 (49.1)a | 1,150 (60.4)a | |
| RR | 855 (65.8)b | 861 (74.9)b | 0.206 |
| ROM | 848 (99.2)c | 856 (99.4)c | 0.511 |
| Total | 2,643 | 1,905 | |
| RR | 1,231 (46.6)b | 1,056 (54.4)b | 0.052 |
| ROM | 1,039 (84.4)c | 1,036 (94.4)c | 0.161 |
The numbers in parentheses are percentages. a, Frequency of thyroid FNA samples in each diagnostic category; b, RR among FNA samples in each diagnostic category; c, ROM among surgical specimens in each diagnostic category. *, P<0.05 was considered significant in all tests. ACR TI-RADS, American College of Radiology Thyroid Imaging Reporting and Data System; TBSRTC, The Bethesda System for Reporting Thyroid Cytopathology; ND, nondiagnostic; AUS/FLUS, atypia of undetermined significance/follicular lesion of undetermined significance; FN/SFN, follicular neoplasm/suspicious for follicular neoplasm; SFM, suspicious for malignancy; ROM, risk of malignancy; RR, resection rate; FNA, fine needle aspiration.